Mihaly Hajos, PharmD, PhD
Professor Adjunct
Research & Publications
Biography
Selected Publications
- Cognito’s non-invasive medical device demonstrates durable effects on activities of daily living through OVERTURE open-label extension study. (N2.002)Kern R, Kuang C, Hajos M, Konisky A, Boasso A, Hempel E, Vaughan B, Seshagiri C, Malchano Z, Hendrix S, Saikali K, Massey J, Arjunji R. Cognito’s non-invasive medical device demonstrates durable effects on activities of daily living through OVERTURE open-label extension study. (N2.002). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000205670.
- Safety, tolerability, and efficacy estimate of evoked gamma oscillation in mild to moderate Alzheimer’s diseaseHajós M, Boasso A, Hempel E, Shpokayte M, Konisky A, Seshagiri C, Fomenko V, Kwan K, Nicodemus-Johnson J, Hendrix S, Vaughan B, Kern R, Megerian J, Malchano Z. Safety, tolerability, and efficacy estimate of evoked gamma oscillation in mild to moderate Alzheimer’s disease. Frontiers In Neurology 2024, 15: 1343588. PMID: 38515445, PMCID: PMC10957179, DOI: 10.3389/fneur.2024.1343588.
- Noninvasive Gamma Sensory Stimulation May Reduce White Matter and Myelin Loss in Alzheimer’s DiseaseDa X, Hempel E, Ou Y, Rowe O, Malchano Z, Hajós M, Kern R, Megerian J, Cimenser A. Noninvasive Gamma Sensory Stimulation May Reduce White Matter and Myelin Loss in Alzheimer’s Disease. Journal Of Alzheimer's Disease 2024, 97: 359-372. PMID: 38073386, PMCID: PMC10789351, DOI: 10.3233/jad-230506.
- Lobe‐specific changes in white matter volume and myelination following 6‐month 40 Hz gamma sensory stimulation in patients on the Alzheimer’s disease spectrumCimenser A, Da X, Hempel E, Malchano Z, Vaughan B, Megerian J, Hajos M. Lobe‐specific changes in white matter volume and myelination following 6‐month 40 Hz gamma sensory stimulation in patients on the Alzheimer’s disease spectrum. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.073143.
- Sensory‐Evoked 40Hz Gamma Oscillation: A Feasible and Promising Treatment Option for Alzheimer’s DiseaseHajos M, Boasso A, Cimenser A, Shpokayte M, Hempel E, Da X, Seshagiri C, Megerian J, Vaughan B, Malchano Z. Sensory‐Evoked 40Hz Gamma Oscillation: A Feasible and Promising Treatment Option for Alzheimer’s Disease. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.072957.
- Decay in Entorhinal White Matter/Gray Matter contrast in Alzheimer’s Disease Patients is reduced by 40Hz sensory stimulationDa X, Hempel E, Malchano Z, Vaughan B, Megerian J, Hajos M, Cimenser A. Decay in Entorhinal White Matter/Gray Matter contrast in Alzheimer’s Disease Patients is reduced by 40Hz sensory stimulation. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.077337.
- A Randomized, Double‐blind, Sham‐controlled, Adaptive‐Design Pivotal Trial of Sensory Stimulation in Subjects with Alzheimer’s DiseaseBoasso A, Houser C, Hajos M, Newberger J, Seshagiri C, Leach J, Konisky A, Galley A, Hempel E, Dickson S, Hendrix S, Malchano Z, Megerian J. A Randomized, Double‐blind, Sham‐controlled, Adaptive‐Design Pivotal Trial of Sensory Stimulation in Subjects with Alzheimer’s Disease. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.080670.
- EPH230 Estimating Risk of Disease Progression from Mild Cognitive Impairment (MCI) to Alzheimer’s Disease (AD) Using Administrative ClaimsGregory S, Abdelhadi J, Conroy B, Yoon L, Irwin D, Malchano Z, Hajos M, Megerian J, Grundman M, Crosland E. EPH230 Estimating Risk of Disease Progression from Mild Cognitive Impairment (MCI) to Alzheimer’s Disease (AD) Using Administrative Claims. Value In Health 2023, 26: s204-s205. DOI: 10.1016/j.jval.2023.03.2576.
- Coherent Activity in EEG Response to Gamma Sensory Stimulation Predicts Positive Outcome in Cognitive and Functional Abilities, and Brain Atrophy in Subjects with Alzheimer’s Disease (P4-6.004)Cimenser A, Mrozak H, Da X, Travers T, Hempel E, Seshagiri C, Boasso A, Vaughan B, Megerian J, Malchano Z, Hajos M. Coherent Activity in EEG Response to Gamma Sensory Stimulation Predicts Positive Outcome in Cognitive and Functional Abilities, and Brain Atrophy in Subjects with Alzheimer’s Disease (P4-6.004). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.1799.
- Feasibility, Safety, and Efficacy of Gamma Sensory Stimulation as a Novel Therapeutic Intervention for Alzheimer’s Disease (N1.001)Megerian J, Hajos M, Hempel E, Cimenser A, Boasso A, Cotter C, Williams M, Kwan K, Nicodemus-Johnson J, Hendrix S, Vaughan B, Malchano Z. Feasibility, Safety, and Efficacy of Gamma Sensory Stimulation as a Novel Therapeutic Intervention for Alzheimer’s Disease (N1.001). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.1936.
- Age-dependent disruption in hippocampal theta oscillation in amyloid-β overproducing transgenic miceScott L, Feng J, Kiss T, Needle E, Atchison K, Kawabe TT, Milici AJ, Hajós-Korcsok É, Riddell D, Hajós M. Age-dependent disruption in hippocampal theta oscillation in amyloid-β overproducing transgenic mice. Neurobiology Of Aging 2012, 33: 1481.e13-1481.e23. PMID: 22227005, DOI: 10.1016/j.neurobiolaging.2011.12.010.